[Evaluation of the potential use of inactivated influenza centrifuged vaccines with various hemagglutinin levels for immunizing schoolchildren].
The safety, reactogenic properties and immunogenic potency of inactivated influenza centrifuged vaccines with different hemagglutinin content were studied in observations on children aged 11-15 and 7-10 years. According to the results of clinico-laboratory investigations, commercial influenza vaccine and its variant with hemagglutinin content reduced by half were found to be safe and showed faintly pronounced reactogenic properties in children. After vaccination hyperemia developed at the site of injection, moderate in 5% of the vaccinees aged 7-10 years and mild in other vaccinees of both age groups. The immunogenic potency of the preparations was determined by the specific features of influenza virus strains: strain A (H1N1) induced seroconversion in 62-94% and strain A (H3N2), in 67-96% of children.
A V
AV
Slobodeniuk
A S
AS
Shadrin
R A
RA
Andrievskaia
N N
NN
Aleksandrova
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D004341:Drug Evaluation; D006389:Hemagglutinins, Viral / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007114:Immunization; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated
Otsenka vozmozhnosti primeneniia inaktivirovannoĭ grippoznoĭ tsentrifuzhnoĭ vaktsiny s razlichnym soderzhaniem gemaggliutinina dlia immunizatsii deteĭ shkol'nogo vozrasta.